ABOUT CORNING LIFE SCIENCES

Corning Life Sciences is a global, leading manufacturer of lab tools for growing cells, bioprocess manufacturing, liquid handling, benchtop equipment, among other solutions for life sciences. Corning strives to improve efficiencies and develop innovations that enable researchers to harness the power of cells to create breakthrough discoveries in research areas like cancer, primary cells, stem cells, drug discovery, cell and gene therapy and lab automation. Learn more at www.corning.com/lifesciences.

FEATURED ARTICLES

  • There are many reagents available for harvesting anchorage-dependent cells. Options include solutions that are animal-derived, recombinant or fully synthetic. Although some harvesting reagents are more common than others, each can impact cell recovery, viability, and functionality. In this article, we highlight commonly used harvesting reagents and their advantages.

  • Research and therapies involving the human immune system rely heavily on peripheral blood mononuclear cells (PBMCs) isolated from whole blood sources. The Corning X-LAB system is designed to isolate and harvest PBMCs from blood and blood products in a closed, sterile device that is automation-friendly. Here we show how the Corning X-LAB system can deplete more than 99% of red blood cells and 80% of platelets.

  • Microcarriers enable efficient cell scale-up in controlled bioreactors. Effective cell recovery from microcarriers often requires the use of concentrated enzymes, extended treatment times, and continuous centrifugation/filtration cycles, which can negatively affect cell health and recovery yield. To address these challenges, Corning Life Sciences developed a calcium-crosslinked polygalacturonic acid (PGA) microcarrier that can be dissolved using EDTA and pectinase. Here we describe the characterization of the PGA polymer, dissociation reagents, and the byproducts of bead dissolution and evaluate their impact on subsequent cell growth.

  • As cell therapy trials advance from pre-clinical research to late-stage trials, cell culture platforms will need to meet increasing demands for cell yield. Establishing an adherent culture platform that can scale from relatively small needs of pre-clinical studies through Phase I/II trials and into Phase III will be a challenge. In this study, the CellCube system was used for expansion of two commonly used bioproduction cell lines – HEK293T and Vero - resulting in final harvest yields for both HEK293T and Vero cell lines greater than 10 billion cells.

  • Nothing's more maddening than cells that won't grow or cell cultures that won't attach. Stunted cell growth and erratic culture behavior can delay projects, frustrate teams, and leave researchers wondering what went wrong and how they can fix it. Issues tend to be associated with culture technique, incubation, and media. Let's explore a few of these pain points and how you can preempt their effects with good practices.

  • Scientists had been increasingly using viral vectors in therapeutic research well before the coronavirus pandemic, as their use in gene therapy and cell therapy has proven promising. Now, those same applications are being repurposed to develop a coronavirus vaccine. However promising they might be, viral vector workflows come with inherent challenges in scale and process. Fortunately, technology is evolving rapidly, and new solutions to simplify viral vector bioprocessing are continuing to emerge.

  • The vaccine production process is continually refreshed by new tools and technologies which imposes challenges on process development scientists: They're the ones who have to align and optimize new methods and means with legacy products and systems. By carefully crafting a customized modular process from end to end, process development scientists can glean the benefits of new technologies without starting from scratch with each new iteration. How can researchers working on vaccine production optimize their process with customization in mind?

  • Regardless of your lab's size or scale, there will come a time when you need a customized solution for your media, sera, or reagents. Off-the-shelf lab products are great for many production needs, but scientists often find themselves searching for tailor-made options when the standard catalog doesn't quite fit the project. Many labs are realizing the value that custom products can bring to day-to-day operations. Here's what you should consider as you contemplate your options for bespoke lab products.

  • Autologous fat grafting is the least invasive method for breast reconstruction, but also has major drawbacks, including high tissue resorption rates of up to 80%. Researchers in Denmark had a hypothesis: what if you could enrich the human fat graft with autologous adipose stem cells (ASCs) to increase graft survival? But they faced a major obstacle: how do you culture a sufficient volume of stem cells to increase grafting success? They turned to Corning, who designed a scale-up solution that’s enabling them to grow the billions of stem cells required to move forward with this clinical study.

  •  An Ottawa Hospital Research Institute’s Cell Manufacturing Facility successfully conducted a Phase I clinical trial examining the safety and efficacy of allogeneic bone marrow-derived MSCs as a treatment for patients experiencing septic shock. Before initiating clinical Phase II studies, the protocol for generating large quantities of MSCs had to be established to reduce end-product variability, minimize production costs, and to ensure sufficient yield to treat multiple patients. Maximizing the yield of viable cells proved challenging in a limited footprint.

  • Considering everything it takes to scale up gene therapy — the platforms, the media, the surfaces, the vessels, the equipment — developing viral vector production processes comes with many challenges. It's no surprise, then, that labs sometimes miss a few things when scaling their gene therapeutics up or out, and those oversights can set projects back. In this article an industry expert identifies four essential things to know about scaling gene therapy processes.

  • Introduced in 2010, Corning HYPERStack vessels have become an industry-standard for a variety of adherent cell expansion applications, including viral vector manufacturing and stem cell expansion.  This e-book is a compilation of research experiences in stem cell, viral vector and vaccine production.

  • When considering an adoptive cell therapy approach, the transfusion of a sufficient number of CAR-T cells with an appropriate phenotype is critical. Corning KBM581 has been shown to be a nutritious, safe, and serum-free medium for other immune cell therapies, such as CIK and NK cells. To discover which medium among several commercialized media (including KBM581) is most appropriate for supporting CAR-T cell growth, the research group from Bioraid Bio generated CAR-T cells and analyzed the expansion folds and phenotype between different media in this application note.

  • The existence of an adaptive immune system in single-cell organisms was debated for a long time until the CRISPR/Cas9 mechanism had been identified. In this study, the CRISPR/Cas9 system was used to knock-out PD-1 gene expression in human primary T cells.

  • Peripheral blood mononuclear cells (PBMCs) are valuable for both clinical and research applications. Isolating pure populations of PBMCs from whole blood traditionally requires sample dilutionand use of a density gradient medium to deplete red blood cells (RBC), granulocytes (GRN) and platelets (PLT). This open, manual process involves a high risk of contamination and is made up of multiple tedious steps.  The Corning X-LAB System is a functionally closed, sedimentation-based system that reliably and reproducibly isolates PBMCs without the need for density gradient media or manual transfer steps.

  • Peripheral Blood Mononuclear Cells (PMBCs) are often counted using time-consuming manual methods such as a hemocytometer. While the hemocytometer has been considered the gold standard for cell counting since the 18th century, results are frequently subjective, variable, and small differences in cell diameters cannot easily or reproducibly be discerned. The Corning Cell Counter offers an alternative method to quickly and accurately count these cells.

  • Closed cell culture systems play a significant role in reducing the risk of contamination during liquid handling. The Corning 100 mm aseptic transfer cap (ATC) offers a closed system solution for transferring liquid aseptically into or out of a Corning 5L Erlenmeyer flask. Here we demonstrate the use of the ATC to seed and expand two suspension cell lines, 5/9 m alpha3-18 and Sf9 cells in the 5L Erlenmeyer flasks.

  • CAR T cells are often counted using time consuming manual methods such as a hemocytometer. While the hemocytometer has been considered the gold standard for cell counting since the 18th century, results are frequently subjective, variable, and small differences in cell diameters cannot easily or reproducibly be discerned. This application note demonstrates the Corning Cell Counter offering an alternative method to quickly and accurately count these cells.

  • HEK-293F is a variant of the HEK-293 cell line that has been adapted for suspension growth. As the HEK-293F expression system permits the transfection of large volumes of cells, demonstrates high transfection efficiencies, and eliminates the need for changing media, many laboratories use this suspension cell culture system for generating large amounts of mammalian recombinant proteins. In this study, we assessed the performance of Corning 5L Erlenmeyer flasks with different media fill volumes on the growth of HEK-293F cells.

  • To achieve large-scale cell production, a microcarrier culture scale-up strategy is necessary. Several approaches have been developed to achieve the transfer of cells from one microcarrier to another including enzymatic dissociation and bead-to-bead transfer. However, enzymatic dissociation introduces additional process steps (washing, inactivation, and removal of the enzyme) that are not feasible at a large scale. This report describes a method for expansion of anchorage-dependent cells on polystyrene Corning microcarriers with an enhanced attachment surface treatment in serum-free cell culture medium.